ClinicalTrials.gg
CompletedNCT04071899SEV-TCSPUpdated Nov 17, 2026

French Validation of a Severity Scale in REM Sleep Behavior Disorder (SEV-TCSP)

An observational study in REM Sleep Behavior Disorder, sponsored by University Hospital, Clermont-Ferrand. Completed at 5 sites in France. Open to participants aged 30 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

Updated Nov 17, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
188
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in REM Sleep Behavior Disorder with a site in France — 6 open to participants now, 6 under way, none of them phase 3. REM Sleep Behavior Disorder · France.

Started
2019
the only one that year
Observational
5 of 15
3 open now
Registered
8th of 15
by date
Lead sponsor
6 of 15
University Hospital, Clermont-Ferrand

Among the 15 studies in REM Sleep Behavior Disorder with a site in France, this one is the only one that started in 2019, is one of 5 observational ones, and was the 8th registered.

REM Sleep Behavior Disorder

101 studies on the registry are indexed under REM Sleep Behavior Disorder; 45 are open to participants now.

Browse REM Sleep Behavior Disorder studies →

Open to participants now

6 of the 15 studies in REM Sleep Behavior Disorder with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 32 REM Sleep Behavior Disorder studies recruiting now, 18 (56%) set no upper age limit and 4 (13%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in REM Sleep Behavior Disorder with a site in France, or all of them as a file.
02

Study summary

REM (Rapid Eye Movements) Sleep Behavior Disorder (RBD) is a parasomnia characterized by episodes of elaborate or violent motor activity during dreams, which can lead to injury and sleep disruption in patient and / or his/her spouse. This is due to the loss of the normal muscle atonia during REM Sleep. RBD is often associated to neurodegenerative diseases, and may even precede them for several years as an early marker. Currently, there is no scale or tool for assessing the severity of RBD. Nevertheless, it is crucial to have a tool of severity when one wants to study the natural evolution of this disorder, as well as the possible effect of a drug in the context of a clinical trial. A Severity Scale of RBD has recently been proposed within the International RBD Study Group and an international validation study in several languages is being considered.

The main objective of this study is to validate a new scale of severity of the REM sleep behavior disorder (RBD Severity Scale or RBDSS) and to characterize its metrological properties, in particular its concurrent validity, internal consistency and reproducibility

Read the detailed description

Research involving the human person, non-interventional, category 3

80 patients with RBD of any etiology (eg Idiopathic RBD, RBD associated with Parkinson's Disease, Multiple System Atrophy, Narcolepsy etc.) and their bedpartners (if available) will be include in 5 French centers (Clermont-Ferrand, Paris, Nantes, Montpellier et Lyon) Patients, and their bedpartners (if available), will be seen 2 times at 1 week intervals.

For the patients Visit 1 (Day 0): duration : 60 minutes

  • Information to patient and collection of non-opposition
  • Collection of socio-demographic data: age, sex, level of education
  • Clinical data collection: duration of RBD, duration and severity of the concomitant disease:, medical and surgical history
  • Assessment of cognitive functions: Mini Mental State Examination
  • Verification of inclusion / exclusion criteria
  • Ongoing treatments and calculation of Levodopa Equivalent Daily Dose (LEDD) for PD patients.
  • RBD severity scale for Patient (RBDSS-PT) + Global Clinical Impression-Severity Scale

Visit 2 (J7) : duration : 20 minutes

  • Ongoing treatments
  • RBDSS PT + Global Clinical Impression-Severity Scale (CGI-S-PT)
  • Patient will be given a Weekly Severity Agenda for 4 weeks plus a copy of the RBSSS-PT + Global Clinical Impression-Severity Scale

At home, patients will fill :

D8 à D36 :

  • Weekly Severity Agenda (wRBDQ) for 4 weeks

D36 :

  • RBDSS-PT + Clinical Global Impression-Severity These documents will be mailed back in a pre-payed envelop. For the Bed Partners Visit 1 (D0- baseline): duration: 30 minutes
  • Information of and collection of non opposition
  • Collection of socio-demographic data: age, sex, level of education
  • Assessment of cognitive functions: Mini Mental State Examination
  • Verification of inclusion / exclusion criteria
  • Ongoing Treatments
  • RBD severity scale of the bed partner (RBDSS BP)+ Global Clinical Impression-Severity Scale

Visit 2 (D7- retest) : duration : 20 minutes

  • Ongoing treatments
  • RBDSS-BP + Clinical Overall Impression Severity Scale
  • Patient will be given a Weekly Joint Severity Agenda to be completed together with the patient, (wRBDQ) for 4 weeks, plus a copy of the RBDSS-BP + CGI-S-BP

At home: bedpartners will fill:

D8 à D36 :

  • Weekly Severity Agenda for 4 weeks, in common with patient

D36 :

  • RBDSS-BP + Impression Global Clinique-Severity scale These documents will be mailed back in a pre-payed envelop.
03

Conditions studied

  • REM Sleep Behavior Disorder

Keywords

  • REM Sleep Behavior Disorder
  • Validation scale
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with RBD and their bedpartner

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • RBD patients:

    • Men or women aged 30 to 80
    • Patients with idiopathic and secondary RBD (including RBD associated with Parkinson's disease, Narcolepsy, Multiple System Atrophy or other neurological diseases) diagnosed according to the latest international criteria Classification of Sleep Disorders (ICSD-3 ).
    • Cooperation and understanding to strictly comply with the conditions laid down in the protocol
    • Affiliated to a social security system
    • bedpartners
    • Men or women aged 30 to 80
    • Subjects sharing the same bed as the patient for ≥70% of the time (e.g. at least 5 nights / week, or 20 nights / month)
    • -Cooperation and understanding to strictly comply with the conditions described in the protocol
    • Affiliated to a social security system

Exclusion criteria

Exclusion Criteria:

-- RBD patients:

  • Clinically defined dementia according to the criteria of DSM-V2 (Major Neurocognitive Disorder)
  • Untreated Obstructive Sleep Apnea Syndrome (OSAS) (with IAH> 15 / h at vPSG)
  • Patients under tutorship or curatorship or safeguard of justice
  • No change in treatment should have occurred during the 4 weeks prior to inclusion in the study and no change in treatment should be expected a priori within one week of inclusion
  • Bedpartners
  • Clinically defined dementia according to the criteria of DSM-V2 (Major Neurocognitive Disorder)
  • Patients under tutorship or curatorship or safeguard of justice
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
188 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients

    patients with RBD

    Other: Scale vaidation

  • Bedpartners

    Subjects which are the bedpartners of patients with RBD

    Other: Scale vaidation

Interventions

  • OtherScale vaidation

    It's just filling a scale in order to validate it in French

06

What researchers measure

Primary outcomes

  1. French validation of a new scale of severity of REM Sleep behavior disorder for patient

    The scale contains 8 items in the patient version. Each of them focusing on one RBD symptom, are evaluated in terms of their frequency and severity. This scale was administered at Day7 to evaluate concurrent validity, internal consistency and reproducibility

    Time frame: Day 7

  2. French validation of a new scale of severity of REM Sleep behavior disorder for patient

    The scale contains 8 items in the patient version. Each of them focusing on one RBD symptom, are evaluated in terms of their frequency and severity. This scale was administered at Day 0 to evaluate concurrent validity, internal consistency and reproducibility

    Time frame: Day 0

Secondary outcomes

  1. French validation of a new scale of severity of REM Sleep behavior disorder for bedpartners

    The scale contains 6 items in the patient version. After two introductory questions that are not scored, the scale includes items concerning the spouse's RBD symptoms and are evaluated in terms of their frequency and severity. This scale was administered at Day 7 to to evaluate concurrent validity, internal consistency and reproducibility

    Time frame: Day 7

  2. French validation of a new scale of severity of REM Sleep behavior disorder for bedpartners

    The scale contains 6 items in the patient version. After two introductory questions that are not scored, the scale includes items concerning the spouse's RBD symptoms and are evaluated in terms of their frequency and severity. This scale was administered at Day 0 to to evaluate concurrent validity, internal consistency and reproducibility

    Time frame: Day 0

  3. Evaluation of the psychometric properties of the patient scale according to the etiology of the RBD

    The total pool of patients will be divided into different groups according to the etiology (RBD-Idiopathic, RBD-parkinsons disease, RBD- Multiple System Atrophy, RBD-Narcolepsy etc.) and the validity in each condition will be evaluated

    Time frame: Day 7

  4. Evaluation of the fluctuations in the frequency and severity of RBD symptoms and their "night-to-night" variability through the collection of daily data over a four-week period

    In order to control variability of symptoms, patients and their bed partners will complete a Weekly Symptom Diary (weekly-RBD Questionnaire), measuring the frequency and severity of symptoms daily for 4 weeks to determine the fluctuation of symptoms over a long period

    Time frame: Day 28

  5. Evaluation of the RBD severity using Clinical Global Impression-Severity

    This scale is s the only currently available measure of severity of RBD. It includes 7 categories that are from 1 to 7: Normal (no symptoms), Minimal, Light, Moderate, Marked, Severe, Very Severe

    Time frame: Day 7

07

Study locations

5 sites
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63000, France
  • Hôpital de la Croix Rousse
    Lyon, 69004, France
  • Clinique beausoleil
    Montpellier, 34070, France
  • CHU Nantes
    Nantes, 44000, France
  • AP-HP
    Paris, 75013, France
08

References and documents

Publications

  • Fantini ML, Postuma RB, Puligheddu M, Rieu I, Venel E, Figorilli M, Cochen-DeCock V, Leclair-Visonneau L, Arnaldi D, Mattioli P, Peter-Derex L, Ricordeau F, Terzaghi M, Arnulf I, Stefani A, Videnovic A, Chirol C, Pereira B; International RBD Study Group. Validation of the International REM Sleep Behavior Disorder Study Group Symptoms Severity Scale (IRBD-SSS): a new tool to assess RBD clinical severity. J Neurol. 2024 Nov;271(11):7264-7271. doi: 10.1007/s00415-024-12702-9. Epub 2024 Sep 27. PubMed 39327269 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2019 to primary completion in Nov 2021, 29 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jun 2020 → Nov 2021 and completion Sep 2020 → Nov 2021.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2019
First posted
Aug 28, 2019
StartActual
May 24, 2019
Primary completionActual
Nov 22, 2021was Jun 2020
CompletionActual
Nov 22, 2021was Sep 2020
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Primary completion
Jun 24, 2020→Nov 22, 2021 (actual)
Nov 17, 2026
Study completion
Sep 24, 2020→Nov 22, 2021 (actual)
Nov 17, 2026
Enrollment
80 (estimated)→188 (actual)
Nov 17, 2026
Publications
Results publication added: Fantini ML, Postuma RB, Puligheddu M, Rieu I, Venel E, Figorilli M, Cochen-DeCock V, Leclair-Visonneau L, Arnaldi D, Mattioli P, Peter-Derex L, Ricordeau F, Te… PubMed 39327269 ↗
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    Publications Results publication added: Fantini ML, Postuma RB, Puligheddu M, Rieu I, Venel E, Figorilli M, Cochen-DeCock V, Leclair-Visonneau L, Arnaldi D, Mattioli P, Peter-Derex L, Ricordeau F, Te… PubMed 39327269 ↗
    Primary completion Jun 24, 2020→Nov 22, 2021 (now actual)
    Study completion Sep 24, 2020→Nov 22, 2021 (now actual)
    Enrollment 80 (estimated)→188 (actual)
    + 3 other changes: criteria formatting, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04071899
Collaborators
Société Française de Recherche et Médecine du Sommeil
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
May 24, 2019
Primary completion
Nov 22, 2021
Completion
Nov 22, 2021
Last update
Nov 17, 2026

Study contacts

Maria-Livia Fantini
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion